Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of oncology therapies. Its lead candidate is pelareorep, an intravenously delivered immunotherapeutic agent being studied for hormone receptor-positive, HER2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. The company also has an agreement with Roche Holding AG to supply atezolizumab for use in ongoing sponsored studies. Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Canada, and its common stock trades on the NASDAQ under the symbol ONCY.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ONCY
|
$0.69
|
-9.8% Downside
|
Fair
|
$4.20
|
444.9% Upside
|
Bargain
|
Weak
|
0.0%
|
November 13, 2026
|
98.183 M
|
94.516 M
|
0.5%
|
98.1%
|
-93.5
|
71.3%
|
